A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

European Journal of Cancer

Volumn 39, Issue 4, 2003, Pages 447-453

  Rahko, E ^a   Blanco, G ^a   Soini, Y ^b   Bloigu, R ^b   Jukkola, A ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

Anthracycline; Breast cancer; c erbB 2; p53; Predictive factor; Prognosis

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0037363440     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00499-9     Document Type: Article

References (25)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;1-15.
2. Overgaard J., Yilmaz M., Guldberg P.et al. TP53 Mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 39:2000;327-333.
3. Knoop A., Bentzen S., Nielsen M.et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 19:2001;3376-3384.
4. Ferrero J.-M., Ramaioli A., Formento J.-L.et al. P53 determination alongside classical prognostic factors in node-negative breast cancer. an evaluation at more than 10-year follow-up Ann Oncol. 11:2000;393-397.
5. Reed W., Hannisdal E., Boehler P.J.et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 Years. Cancer. 88:2000;804-813.
6. Turner B.C., Gumbs A.A., Carbone C.J.et al. Mutant p53 protein overexpression in women with ipsilateral breast tumour recurrence following lumpectomy and radiation therapy. Cancer. 88:2000;1091-1098.
7. Berns E.M.J.J., Klijn J., Smid M.et al. Tp53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer. 16:1996;170-179.
8. Elledge R.M., Green S., Howes L.et al. BCL-2, p53 and response to tamoxifen in estrogen receptor-positive metastatic breast cancer. a Southwest Oncology Group study J. Clin. Oncol. 15:1997;1916-1922.
9. Berns E.M.J.J., Klijn J.G.M., van Putten W.L.J.et al. P53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J. Clin. Oncol. 16:1998;121-127.
10. Clahsen P.C., van de velde C.J.H., Duval C.et al. P53 accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 16:1998;470-479.
11. Muss H.B., Thor A.D., Berry D.A.et al. C-erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330:1994;1260-1266.
12. Niskanen E., Blomqvist C., Franssila K.et al. Predictive value of c-erb-B2, p53, cathepsin D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer. 76:1997;917-922.
13. Rozan S., Vincent-Salomon A., Zafrani B.et al. No significant predictive value of c-erb-B2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer. 33:1998;27-33.
14. Borg A., Baldetorp B., Fernó M.et al. ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene. 6:1991;137-143.
15. Carlomagno C., Perrone F., Gallo C.et al. C-erb-B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14:1996;2702-2708.
16. Elledge R.M., Green S., Ciocca D.et al. HER-2 expression and response to tamoxifen in estrogen receptor positive breast cancer. a Southwest Oncology Group study Clin. Cancer Res. 4:1998;7-12.
17. Jukkola A., Bloigu R., Soini Y.et al. C-erb-B2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur. J. Cancer. 37:2001;347-354.
18. Galea M., Blamey R., Elston C.et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat. 22:1992;207-219.
19. Meng L., Lin L., Zhang H.et al. Multiple mutations of the p53 gene in human mammary carcinoma. Mutat. Res. 435:1999;263-269.
20. Chappuis P.O., Estreicher A., Dieterich B.et al. Prognostic significance of p53 mutation in breast cancer. frequent detection of non-missense mutations by yeast functional assay Int. J. Cancer. 84:1999;587-593.
21. Bergh J., Norberg T., Sjögren S.et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Medicine. 10:1995;1029-1034.
22. Beenken S., Grizzle W., Crowe R.et al. Molecular biomarkers for breast cancer prognosis. coexpression of c-erbB-2 and p53 Ann. Surg. 5:2001;630-638.
23. Nakopoulou L., Alexiadou A., Theodoropoulos G.et al. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J. Pathol. 179:1996;31-38.
24. Hamilton A., Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer. a review of the literature on HER-2, p53 and BCL-2 Ann. Oncol. 11:2000;647-663.
25. Lavarino C., Pilotti S., Oggioni M.et al. P53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J. Clin. Oncol. 23:2000;3936-3945.